Compare Regeneron Pharmaceuticals Inc (REGN) vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. (ZTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $20.15 (market cap $14.70B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.2× ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.'s market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| REGN | ZTO | |
|---|---|---|
Market Cap | $76.14B | $14.70B |
Volume | 500,239 | 1,484,646 |
Sector | Health | Industrials |
52-Week High | $852.03 | $25.88 |
52-Week Low | $557.73 | $18.50 |
Typical Hold Time | 107 Days | — |
Enterprise Value | $70.85B | $13.32B |
Dividend Yield | 0.51% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.
ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.
Read more on ZTO →
